Saruparib

DB18982InvestigationalSmall molecule

Saruparib is under investigation in clinical trial NCT06380751 (Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in Hr-positive, Her2-negative (IHC 0, 1+, 2+/ ISH...

Formula / weight: C₂₂H₂₆N₆O₂ · 406.49 g/mol (avg)
Also known as: 2-Pyridinecarboxamide, 5-[4-[(7-ethyl-5,6-dihydro-6-oxo-1,5-naphthyridin-3-yl)methyl]-1-piperazinyl]-N-methyl- · 5-{4-[(7-ethyl-5,6-dihydro-6-oxo-1,5-naphthyridin-3- yl)methyl]piperazin-1-yl}-N-methylpyridine-2- carboxamide
Code names: AZD-5305

Resolves to

Compound

UNII16MZ1V3RBTCAS2589531-76-8ChEMBLCHEMBL5095220

Structure

InChIKeyWQAVGRAETZEADU-UHFFFAOYSA-NSMILESCCC1=CC2=NC=C(CN3CCN(CC3)C3=CC=C(N=C3)C(=O)NC)C=C2NC1=O

Targets

P09874PARP1

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

20Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Saruparib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account